The two evolved candidate vaccines opposed to coronavirus disease (Covid-19) have shown a fair protective profile, Union Minister of State Ashwini Kumar Choubey said in a written reaction to Lok Sabha.
However, immunogenicity tests, to determine if the vaccine is the cause of the body’s immune response, are still ongoing, the minister added.
Bharat Biotech International Ltd’s total inactivated virus candidate vaccine (BBV152) for SARS-CoV-2, the virus that causes Covid-19, is an evolved viral isolate (NIV-2020-770) provided through the Indian Medical Research Council (ICMR) -National Institute of Virology (NIV), Pune.
Characterization of the candidate vaccine performed in ICMR-NVNI, followed by studies of protection and tolerability in small animals such as rats, mice and rabbits.
“Phase I clinical trials and parallel hamster and rhesus macaque studies have been completed. The trial revealed protection of the vaccine candidate. Immunogenicity testing is underway. Phase II clinical trials are underway,” he said. Choubey’s reaction.
Another candidate vaccine manufactured in India through Cadila Health Ltd. is a DNA-based vaccine (ZyCov-D). Preclinical toxicity studies have been conducted in small animals: mice, rats, rabbits and guinea pigs. The vaccine was found to be immunogenic. Cadila has been associated with ICMR for parallel preclinical studies in rhesus macaques.
The prestige of clinical trials for this candidate vaccine is the same as that of the Bharat Biotech candidate vaccine, as phase I clinical trials have been completed, revealing the protection of the candidate vaccine. Immunogenicity tests are ongoing and Phase II clinical trials are underway.
In addition, the Serum Institute of India (IBS) and ICMR have partnered for the clinical progression of two candidate vaccines worldwide that are at other testing stages.
“ChAdOx1-S, a non-replication viral vector vaccine developed through the University of Oxford-AstraZeneca, is found in Phase III clinical trials in Brazil. Phase II/III transition studies have been introduced through ICMR at 14 clinical trial sites. -National Institute for Tuberculosis Research (NIRT), Chennai is the leading institution. ICMR and IBS have also been associated for the clinical progression of a subsequent glycoprotein from an adjuvant nanoparticle vaccine developed through Novavax in the United States. October after the vaccine is manufactured through the ISS. The trial is being conducted through the ICMR-National AIDS Research Institute (NARI), Pune,” Choubey said.
According to the Department of Biotechnology and the Department of Science and Technology, the government has supported at least 30 candidate vaccines that are currently in development stages.
“item. title”